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Abstract
A sensitive and specific liquid chromatography-mass spectrometry (LC-MS) method has been
developed and validated for the enantioselective determination of ifosfamide [(R)-IF and (S)-IF] in
human plasma and for the detection of the N-dechloroethylated metabolites of IF, 2-N-
dechloroethylifosfamide [(R)-2-DCl-IF and (S)-2-DCl-IF] and 3-N-dechloroethylifosfamide [(R)-3-
DCl-IF and (S)-3-DCl-IF]. IF, 2-DCl-IF and 3-DCl-IF were extracted from plasma using solid-phase
extraction and resolved by liquid chromatography on a column containing a Chirabiotic T chiral
stationary phase. The enantioselective separations were achieved using a mobile phase composed of
2-propanol:methanol (60:40 v/v) and a flow rate of 0.5 ml/min. The observed enantioselectivities
(α) for IF, 2-DCl-IF and 3-DCl-IF were 1.20, 1.17 and 1.20, respectively. The calibration curve was
linear in the concentration range of 37.50-4800 ng/ml for each ifosfamide enantiomer (r2 > 0.997).
The lower limit of detection (LLOD) was 5.00 ng/ml. The inter- and intra-day precision ranged from
3.63 to 15.8 % relative standard deviation (RSD) and 10.1 to 14.3 % RSD, respectively, and the
accuracy ranged from 89.2 to 101.5 % of the nominal values. The method was applied to the analysis
of plasma samples obtained from a cancer patient who received 3.75 g/m2/d dose of (R,S)-ifosfamide
as a 96-h continuous infusion.
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Introduction
Ifosfamide (IF; Fig. 1) is an alkylating oxazaphosphorine anticancer agent routinely used in
the treatment of a variety of pediatric and adult tumors including soft tissue sarcomas and
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lymphomas [1-5]. IF contains a chiral center at the phosphorus atom and is clinically
administrated as a racemic (50:50) mixture of (R)-IF and (S)-IF.
IF is a prodrug and requires biotransformation via cytochrome P450 (CYP) enzymes in order
to exert its cytotoxic activity. The hepatic metabolism of IF has been extensively studied and
occurs in the liver by two major pathways, Fig. 1 [6-11]. One pathway involves the 4-
hydroxylation of IF and eventually leads to the production of the cytotoxic isophosphoramide
mustard [6]. The 4-hydroxylation of R-IF is catalyzed by CYP3A4 and the 4-hydroxylation of
S-IF by CYP2B6 [10,11].
The second pathway involves the oxidation of either the exocyclic-N2- or endocylic-N3-
chloroethyl moieties producing the therapeutically inactive 2-N-dechloroethyl-ifosfamide
[(R)- and (S)-2-DCl-IF] and 3-N-dechloroethylifosfamide [(R)- and (S)-3-DCl-IF] [6,12], Fig.
1. (S)-IF is metabolized to (R)-3-DCl-IF by CYP3A4 and (S)-2-DCl-IF by CYP2B6 while the
(R)-IF enantiomer is metabolized to (R)-2-DCl-IF by CYP3A4 and (S)-3-DCl-IF by CYP2B6,
where the apparent change in configuration at the chiral phosphorous moiety is a function of
the Cahn-Ingold-Prelog nomenclature [11,13].
Clinically, the N-dechloroethylation pathway has been associated with treatment-ending
central nervous system (CNS) toxicity [5,7-9]. The N-dechloroethylation pathway is
regioselective and enantioselective [10,11] and, as a result, (R)-IF and (S)-IF have distinct
efficacy and toxicity profiles. Clinical studies and in in vitro experiments have demonstrated
that (S)-IF is more extensively cleared by N-dechloroethylation than (R)-IF [9,14-17]. In
addition, clinical studies have indicated that treatment related CNS toxicities were associated
with inter-patient variations in the cumulative urinary excretion of the (S)-IF metabolite (R)-3-
DCl-IF [9,16]. Thus, it is important that clinical studies include an enantioselective
determination of the disposition of (R)- and (S)-IF as well as a measurement of the relative
concentrations of their N-decholorethylated metabolites [16,17].
A number of enantioselective gas chromatography and HPLC methods have been developed
for quantifying (R)- and (S)-IF and their respective N-dechloroethylated metabolites. Gas
chromatography methods utilizing chiral stationary phases (CSPs) coated on glass capillaries
have been extensively used for the enantioselective analysis of IF enantiomers in human plasma
and urine [14,18-21]. These assays were also capable of the enantioselective resolution of 2-
DCl-IF and 3-DCl-IF and, when coupled with mass spectrometric or nitrogen-selective
detectors, able to quantify these compounds in biological matrices.
HPLC has also been used to resolve (R,S)-IF by applying different methods of detection
including ultraviolet [22], fluorescence [10,15] or mass spectrometry detection [14,17,23,24].
Blaschke reported the initial separation using a polyacrylamide CSP [25] and subsequent
enantioselective separations were achieved using the Chiracel OD [26] and AGP [27] CSPs.
The latter assays were validated and used to assay plasma samples obtained during clinical
studies. The Chiracel OD CSP was also used to simultaneously enantioselectively resolve
(R,S)-IF, (R,S)-2-DCl-IF and (R,S)-3-DCl-IF in plasma and urine, but the liquid
chromatography assay was not validated or applied to samples obtained during a clinical study
[21].
However, a key problem in the application of enantioselective HPLC methods to routine
clinical analysis is the fact that IF and its N-dechloroethylated metabolites lack a strong
chromophore, see Fig. 1. When UV detection was used, the target compounds were monitored
at λ = 205-210 nm, which made the analysis difficult due to solvent absorption at the same
wavelength. A more sensitive achiral LC-MS method for the separation and analysis of IF and
its N-dechloroethylated metabolites in rat microsomal medium has been recently reported
[23], and our laboratory has reported preliminary results with an enantioselective LC-MS
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method [28]. In the latter approach, (R,S)-IF and (R,S)-2-DCl-IF were enantioselectively
resolved using a CSP containing the macrocyclic antibiotic teicoplanin, the Chirabiotic T CSP,
and detected by mass spectrometry using either an electrospray or atmospheric pressure
chemical ionization interface. However, (R,S)-3-DCl-IF was not enantioselectively separated
under the chromatographic conditions used in the study [28].
We now report the development and validation of an enantioselective LC-MS assay for the
determination of (R)- and (S)-IF in human plasma. The assay utilizes the Chirabiotic T CSP
chiral column and the chiral separations were achieved using a polar organic mode, where the
mobile phase was composed of 2-propanol:methanol (60:40 v/v) solvents. The reported method
is also able to enantioselectively resolve (R,S)-2-DCl-IF and (R,S)-3-DCl-IF and can be used
to determine the relative concentrations of the compounds in human plasma. The assay has




(R, S)-IF was obtained from Sequoia Research Products Ltd (Oxford, UK). (R)-IF and (S)-IF
were prepared by Advanced Separation Technologies Inc. (Whippany, NJ, USA) using an
enantioselective HPLC separation of (R,S)-IF accomplished using a Chirabiotic T2 (10μm)
chiral column and a mobile phase composed of water:2-propanol (80:20 v/v) delivered at a
flow rate of 30 ml/min. (R, S)-2-DCl-IF and (R,S)-3-DCl-IF were generously provided by the
Central Analytical Services Department of Asta Group Research (Frankfurt, Germany). (R)-
IF and (S)-IF standards were kindly provided by Prof. G. Blaschke (Westfalishe Wilhelms-
Universität Münster, Münster, Germany).
HPLC grade 2-propanol, methanol, acetonitrile, ethanol and hexane were purchased from
Fisher Scientific (Fair Lawn, NJ, USA). HPLC-reagent grade ammonium acetate was obtained
from J.T. Baker (Phillipsburg, NJ, USA). Formic Acid 96%, ethylenediaminetetraacetic acid
disodium salt dehydrates 99%, magnesium chloride and β-nicotinamide adenine dinucleotide
phosphate reduced tetrasodium salts were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Purified water was obtained using a Milli-Q water purification system (Millipore, Milford,
MA, USA). Pooled control human plasma was received from the Apheresis Unit, National
Institute on Aging (Baltimore, MD, USA). Solid phase extraction cartridges were Oasis HLB
1cc, 30mg (Waters, Milford, MA, USA). Solid phase extraction was performed using a 12-
port vacuum manifold, PrepSep from Fisher Scientific (Fair Lawn, NJ, USA).
2.2. Equipment
The analytical system consisted of a LC system Series 1100 (Agilent Technologies, Palo Alto,
Ca, USA) equipped with a vacuum degasser (G1322 A), a binary pump (1312 A), an auto
sampler (G1313A), a thermostated column compartment (G1316 A) and a MSD mass
spectrometer fitted with an electrospray ionization source operated in single ion monitoring
(SIM) mode. The designated ions of interest were m/z 283.0 for [M+Na] of R-IF and S-IF and
m/z 199.1 for [M+H] of 2-DCl-IF and 3-DCl-IF. The MSD parameters were optimized and
were as follows: fragmentor: 70V; drying gas flow rate: 10.0 L/min; nebulizer pressure: 35
psig; drying gas temperature: 350 °C and capillary voltage: 3000 V. Data was acquired by
ChemStation software.
2.3. Chromatographic Conditions
The chiral separation of (R)- and (S)-IF, (R)- and (S)-2-DCl-IF and (R)- and (S)-3-DCl-IF was
achieved using a Chirabiotic T column (250 × 4.6 mm I.D., 5 um particle size) connected with
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a Chirabiotic T guard column (20.0 × 4.0 mm I.D.), both purchased from Advanced Separation
Technologies Inc.(Whippany, NJ, USA).
The chromatography was carried out using isocratic elution mode with a mobile phase
consisting of 2-propanol:methanol (60:40 v/v) at a flow rate of 0.5 ml/min. The column was
kept at room temperature and the volume of injection was 10 μl. The auto sampler temperature
was kept at 4°C. (R)- and (S)-IF, (R)- and (S)-2-DCl-IF and (R)- and (S)-3-DCl-IF were
quantified based on calibration curves generated for (R)- and (S)-IF. All analytes were
quantified on the basis of peak area.
2.4. Peak assignment
The identification of the chromatographic peaks corresponding to (R)- and (S)-IF was
accomplished using the (R)-IF and (S)-IF standards provided by Prof. G. Blaschke. The
chromatographic peaks corresponding to (R)- and (S)-2-DCl-IF and (R)- and (S)-3-DCl-IF
were identified by injection of metabolite preparations generated from rat liver microsome
incubations with (R)-IF or (S)-IF. The incubations were carried out using Sprague-Dawley
male rat liver microsomes (pooled from rats approximately 8 weeks of age, 20 mg protein/mL)
purchased from Xenotech, LLC (Leneka, KS,USA) following a previously described protocol
[11]. In brief, the incubations were performed in 1.0 ml total incubation volume containing
610 μl potassium phosphate buffer (100 mM, pH 7.4), 60 μl EDTA (1mM), 30 μl MgCl2
(3mM), 50 μl microsomes (0.5 mg/ml protein), 200 μl NADPH (40 mg/ml), and (S)-IF or (R)-
IF (200 μM). Incubation mixtures minus NADPH were preincubated for 3 min at 37 °C and
then initiated by addition of NADPH. Reactions were carried out in a 37 °C water bath.
Following 180 min of incubation, 890 μl of ammonium acetate buffer [10 mM, pH 8.22] was
added and the samples were extracted by solid phase extraction as described in section 2.5. A
10 μl aliquot of the resulting extract from each incubation was injected onto the
chromatographic system and the order of elution of (R)-2-DCl-IF and (S)-3-DCl-IF was
obtained from the (R)-IF incubation and (S)-2-DCl-IF and (R)-3-DCl-IF from the (S)-IF
incubation. The obtained biotransformation compounds were analyzed under the same
chromatographic conditions described at section 2.3.
2.5. Standard solutions
A stock solution of (R,S)-IF (1000 μg/ml) was prepared in methanol and aliquots were diluted
with methanol to produce eight working solutions at the following concentrations for each
enantiomer: 48.00; 24.00; 12.00; 6.00; 3.00; 1.50, 0.750 and 0.375 μg/ml. Quality control
solutions were prepared in a similar fashion at concentrations of 0.90, 20.00, and 45.00 μg/ml.
Stock, working solutions and quality control solutions were prepared fresh weekly.
Plasma calibration standards and plasma quality controls were prepared on the day of analysis
by spiking the appropriate working standard solution into 100 μl of plasma, or 2-
propanol:methanol (60:40 v/v); the latter was used for the determination of extraction
efficiency.
2.6. Plasma Sample Preparation
After thawing, plasma samples were centrifuged at 15000 × g at 4.0°C for 20 min. Aliquots of
100 μl of plasma were transferred to different glass tubes and 10 μl of appropriate working
standard solution and 890 μl of ammonium acetate buffer [10 mM, pH 8.22] were added to
each tube. The resulting solutions were vortex-mixed for 10 s and transferred to preconditioned
1 ml SPE cartridges. The cartridges were conditioned by eluting two times with 1 ml of
methanol, followed by 1 ml water and then 1 ml of ammonium acetate buffer [10 mM, pH
8.22]. After addition of the total plasma sample (1 ml), the cartridges were washed with 1 ml
of water followed by 1 ml of water:methanol (95:5 v/v). The retained compounds were eluted
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with 1 ml of methanol. The methanol was evaporated to dryness in a Speed Vac (Thermo
Savant, NY) for 10 min at 30°C and the resulting dry residue was dissolved in 100 μl of 2-
propanol:methanol (60:40 v/v), vortex-mixed for 10 sec, transferred into amber vials and 10
μl of the extracted plasma was injected into the HPLC system for analysis.
2.7. Method Validation for (R)-IF and (S)-IF
Linearity was determined using calibration standards prepared as described in Section 2.5.
Eight plasma calibration standards (4.800; 2.400; 1.200; 0.600; 0.300; 0.150, 0.075 and 0.0375
μg/ml) were prepared in triplicate using drug-free plasma. Calibration curves were prepared
daily prior to each batch analysis. Quality controls and diluted quality controls were randomly
included in all analysis to validate each sample run. The calibration curves were obtained by
polynomial linear regression analysis of the peak area of IF versus the nominal concentration
of each IF enantiomer. Calibration curves were used to calculate the concentrations of (R)- and
(S)-IF in the quality control and human samples according to peak area. For selectivity
purposes, analysis of drug-free plasma was included in all analytical runs.
The extraction efficiency of IF from spiked plasma was determined by analyzing quality control
samples at three different concentrations: 0.09; 2.00, and 4.50 μg/ml. The peak area of five
replicates of each extracted quality control was compared with the area of five replicate
injections of quality controls in 2-propanol:methanol (60:40 v/v) at the same concentrations to
derive a percent extraction.
The precision and accuracy of the method was evaluated by replicate analysis of the three
quality control samples (0.09; 2.00, and 4.50 μg/ml). Calibration standards and quality controls
samples in plasma were prepared five times for each concentration on the same day to determine
intra-day accuracy and precision. Precision was estimated from the coefficients of variation
(C.V. %) and the accuracy was evaluated by back-calculation and expressed as the percent
deviation between amount found and amount added at the three concentrations examined.
The acceptance criteria for the limits of quantification were defined as the precision and
accuracy for three extracted samples must be ≤ 20%. The limit of detection was determined
by the lowest concentration of analyte which resulted in a signal-to-noise ratio of three.
The stability of IF in plasma was assessed by analyzing three aliquots of the quality control
samples following storage in different conditions. The stability of IF in plasma was evaluated
under the following conditions: (a) room temperature for 4 h (bench-top stability) and 35 h
after solid-phase extraction (autosampler stability) and (b) after storage at −80°C and exposure
to three freeze-thaw cycles. Variation of less than 15% in the concentration of the samples was
the criteria for the stability evaluation.
2.8. Application of the method
The validated method was applied to the quantification of (R)-IF, (S)-IF and the determination
of the relative concentrations of their corresponding N-dechloroethylated metabolites in human
plasma obtained from cancer patients who had received 3.75g/m2/d dose of (R,S)-IF
administered as a 96-h continuous infusion. The samples were analyzed as part of the protocol
“The relationship of cytochrome P450 3A4 and cytochrome P450 2B6 to the therapeutic index
of high-dose intravenous ifosfamide” (NIA Protocol # 2003-117). After obtaining informed
consent, venous blood samples (7 ml) were collected using heparinized vacutainer tubes at 0
(predose) and 3, 6, 12, 18, 24, 30, 36, 48, 72 and 96 h during the infusion and 0, 2, 4, 6, 12, 18
and 24 h post-infusion.
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3. Results and Discussion
3.1. Optimization of the chromatographic conditions
The initial studies of the LC-MS enantioselective separations of IF, 2-DCl-IF and 3-DCl-IF
on the Chirabiotic T CSP utilized a mobile phase composed of ammonium acetate [10 mM,
pH 7.0] modified with 2-propanol using a gradient of 2-propanol from 5% to 18% [28]. Under
these conditions, IF and 2-DCl-IF were enantioselectively resolved with enatioselectivity
factors (α) of 1.1 for each compound, while 3-DCl-IF was not resolved. In this study, the initial
mobile phase was ammonium acetate [10 mM, pH 7.0]: 2-propanol (90:10, v/v) delivered in
an isocratic mode and the chromatographic results were the same as the previous study (data
not presented).
The effect on the enantioselective separations produced by systematically changing the
reversed phase conditions was investigated. In these studies, the flow rate was altered, 1.0, 0.5
and 0.2 ml/min, the ammonium acetate buffer was replaced by 0.01% formic acid, and the
organic modifier was changed to acetonitrile or methanol. None of these approaches improved
the observed α values for IF and 2-DCl-IF or produced an enantioselective resolution of 3-
DCl-IF (data not presented).
Since IF-related CNS toxicity has been associated with increased production of (R)-3-DCl-IF
[9,16], the enantioselective resolution of (R,S)-3-DCl-IF was one of the key acceptance criteria
for the bioanalytical assay. One of the advantages of the Chirabiotic T CSP is that it has been
shown to achieve enantioselective separations in reversed phase, normal phase and polar
organic modes [29]. Because of the hydrophilic nature of the analytes and the desire to have a
mobile phase that was compatible with mass spectrometric detection, the polar organic mode
was investigated and the effects on retention and enantioselectivity of phases composed of
methanol, ethanol, 2-propanol and acetonitrile were examined, Table 1.
When the mobile phase was composed of methanol or 2-propanol, baseline enantioselective
resolutions of IF, 2-DCl-IF and 3-DCl-IF were achieved, with higher α values, resolution
factors (RS) and retention (k) observed with 2-propanol, Table 1. When acetonitrile was used
as the mobile phase, the target analytes were not enantioselectively resolved and the k for IF
increased relative to the alcohols while the k's for the dechloroethylated metabolites decreased,
Table 1.
With IF, the significant increase in k produced by changing the mobile phase from methanol
to 2-propanol is consistent with the decreased polarity of 2-propanol relative to methanol.
However, when the mobile phase was changed to acetonitrile, the retention also increased
relative to both methanol and 2-propanol, even though the polarity index of acetonitrile is
greater than that of methanol, 5.8 versus 5.1 [30].
As with the retention, the observed enantioselectivity, α and RS, of IF increased by 46% and
27%, respectively when the mobile phase was changed from methanol to 2-propanol, Table 1.
However, when the mobile phase was composed of acetonitrile, the observed enantioselectivity
was lost, even though the retention increased by 86% relative to methanol.
Mixtures of polar organic modifiers, designated as polar organic mode, were also evaluated in
order to shorten analysis times while maintaining enantioselective separation of all compounds.
Since the mobile phase containing 2-propanol provided the best enantioselectivity (α) and
enantiomeric resolution (Rs), Table 1, this solvent was chosen as the primary mobile phase
component. For IF, the addition of methanol or ethanol to the mobile phase resulted in
significant reductions in k ranging from 81% {40% methanol} to 59% {40% ethanol} with
smaller losses in α, 37% {40% methanol} and 21% {40% ethanol}, and no significant changes
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in Rs, Table 1. Similar effects were observed with 2-DCl-IF and 3-DCl-IF except for the Rs
values for 2-DCl-IF which were significantly reduced, although baseline separations were still
achieved, Table 1. The addition of 30% acetonitrile to the mobile phase significantly reduced
k, α and Rs for IF, 2-DCl-IF and 3-DCl-IF, Table 1 and, no further experiments were carried
out using this modifier.
Based on these results, a mobile phase containing 2-propanol:methanol (60:40, v/v) was
selected for use in the study. Under these conditions, the retention times of the enantiomers of
IF were 10.4 and 11.9 min, of 2-DCE-IF, 14.2 and 16.3 min, and of 3-DCE-IF, 18.0 and 20.3
min, Figure 2.
The enantiomeric elution order for IF [(S)-IF elutes before (R)-IF] was established using known
standards. The elution orders of 2-DCl-IF and 3-DCl-IF were also established using known
standards, however, these standards were racemic and we were therefore unable to determine
the enantiomeric elution order. In order to establish the enantiomeric elution orders, (R,S)-IF
was enantioselectively resolved and the two enantiomers were obtained with >93%
enantiomeric purity, Figure 3. The separate enantiomers were then incubated with rat liver
microsomes using previously described conditions known to generate 2-DCl-IF and 3-DCl-IF
[11]. Using this approach, it was established, by means of retention time, that (S)-2-DCl-IF
(peak 3, Figure 3B) eluted before (R)-2-DCl-IF (peak 1, Figure 3A) and that (S)-3-DCl-IF
(peak 2, Figure 3A) eluted before (R)-3-DCl-IF (peak 4, Figure 3B). Because of a change in
the priorities around the chiral phosphorus atom, (R)-IF is the source of (S)-3-DCl-IF and (S)-
IF is the source of (R)-3-DCl-IF, see Figure 1. Thus, in reference to the three-dimensional
configuration of the phosphoramide moiety, the elution order of the 3-DCl-IF enantiomers was
reversed. As discussed above, the chiral recognition mechanism responsible for this
observation will be discussed elsewhere.
3.2. Optimization of the mass spectrometry detection
Parameters such as fragmentor voltage, drying gas temperature, nebulizer pressure and
capillary voltage were optimized to obtain the highest intensity for the protonated molecule.
The optimization was carried out using flow injection analysis of the compounds of interest
and concomitant changes of parameters. The optimal responses were obtained at fragmentor:
70V; drying gas flow rate: 10.0 L/min; nebulizer pressure: 35 psig; drying gas temperature:
350 °C and capillary voltage: 3000 V.
3.3. Matrix effects and sample preparation
In parallel to method development, the matrix effect was also evaluated to guide development
of the sample preparation method. The effects of sample preparation methods on the
electrospray ionization response for (R,S)-IF, (R)-IF, (S)-IF and the 2-DCl-IF and 3-DCl-IF
metabolites were evaluated using a post-column infusion system. Four different sample pre-
treatments were investigated: methyl-t-butyl ether (MTBE) liquid-liquid extraction,
acetonitrile protein precipitation, mixed-mode and reverse mode solid phase extraction. The
four sample preparation methods were used to test a pool of human plasma as matrix.
Large differences in matrix effect were observed between sample preparation techniques (data
not presented). All four sample treatments resulted in some suppression of ESI response. In
general, acetonitrile protein precipitation showed the greatest degree of ionization suppression;
this was expected because of the minimum clean up of the plasma samples by this method.
Further results suggested that solid phase extraction eliminated matrix interferences more
effectively from biological samples and would therefore provide a more robust assay than
liquid-liquid extraction or protein precipitation.
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It is important to note that for quantification of IF in SIM mode, m/z 261.1 [M+H] was initially
selected. However, because of the presence of a co-eluting endogenous interference which
could not eliminated by sample preparation, it was necessary to monitor m/z 283.0 [M+Na] in
order to achieve accurate IF peak integration.
3.4. Method Validation, IF
Selectivity of the LC-MS method was determined by the absence of any endogenous
interference at the retention times of the peaks in plasma from a pre-dose patient compared to
a patient plasma sample obtained 6 h post-infusion of (R,S)-IF, Figure 4.
A suitable internal standard was not available for the quantification of IF and its metabolites.
However, as the method was developed using solid phase extraction for sample treatment,
which requires minimal of sample manipulation, the use of internal standard was not required.
Therefore, calibration curves were generated by polynomial linear regression analysis of the
calculated areas of the peaks corresponding to (R)-IF and (S)-IF versus the nominal
concentration of the respective enantiomers. The calibration curves were linear from 37.5 ng/
ml to 4800 ng/ml for each IF enantiomer with correlation coefficients greater than 0.997.
Sufficient quantities of the 2- and 3-N-decholorethyl metabolities were not available and
calibration curves could not be established for these analytes. Therefore, the concentrations of
these compounds were estimated using the standard curves constructed for (R)- and (S)-IF.
Inter- and intraday precision and accuracy were established at three quality control samples
(high, medium and low concentrations) prepared in five replicates and analyzed on three
nonconsecutive days. The precision was expressed as coefficient of variation (CV%) and the
accuracy was evaluated by back-calculation and expressed as the percent deviation between
amount found and amount added at the three concentrations examined. All precision and
accuracy results led to satisfactory intra- and interday precision, with coefficient of variation
≤ 16.3%. These results obtained are presented on Table 2.
The recovery was determined at the same three quality control concentration levels. The results
were calculated based on comparison to aqueous (R,S)-IF solutions at corresponding
concentrations. The calculated recoveries were >89% at the three concentrations studied, Table
2. For each enantiomer, the limit of quantification (LOQ) was 37.5 ng/ml and the limit of
detection (LOD) was 5 ng/mL.
Short term storage (bench-top), freeze-thaw stability (3 cycles) and autosampler stability were
evaluated. Analytical standard solutions were stable for 15 days when stored at −80°C. For
short-term storage (bench-top) the samples were prepared and kept at room temperature for 4
h before analysis and all were stable. Autosampler stability was also determined and all samples
were stable over the 35 h period evaluated. The stability of (R,S)-IF in spiked-plasma samples
during three freeze-thaw cycles was evaluated and (R,S)-IF was only stable for one cycle.
3.5. Application of the method
The validated method was used to analyze plasma samples obtained from a clinical study
investigating the therapeutic and toxic effects of high dose (R,S)-IF. Representative
chromatograms from a patient before initiation of therapy and 6 h after the end of a 96 h
continuous infusion of 3.75 g/m2/d (R,S)-IF are presented in Figure 4.
Previous clinical studies have demonstrated that the key indicator of CNS toxicity is the relative
concentrations of the DCl metabolites [9,16], and, therefore, the method was also used to probe
these concentrations in the clinical samples. The plasma concentration – time profiles for (R)-
IF, (S)-IF and the corresponding 2- and 3-DCl metabolites are presented in Figure 5. The data
is consistent with previously reported results, c.f. [20].
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The present work reports the development, validation and application of an enantioselective
LC/MS method for the simultaneous quantification of (R)-IF, (S)-IF and the estimation of the
relative concentrations of their corresponding 2-DCl-IF and 3-DCl-IF metabolites. This
method is sensitive and selective and has been used to analyze plasma samples from an on-
going clinical trial. The results of this trial will be reported elsewhere.
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The N-dechloroethylation of (R)- and (S)-ifosfamide by cytochrome P450 enzymes (CYP 3A4
and CYP 2B6) to yield the 2-N-dechloroethyl (2-DCE-IFF) and 3-N-dechloroethyl (3-DCE-
IFF) metabolites. Reprinted with permission from [11].
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The chromatograms of ifosfamide (IF) (A), 2-N-dechloroethyl-IF (2-DCl-IF) (B) and 3-N-
dechloroethyl-IF (3-DCl-IF) (C) on the Chirabiotic T CSP using mobile phase composed of
IPA:methanol (60:40, v/v). where: IPA = 2-propanol.
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The chromatograms obtained after the microsomal metabolism of: A. (R)-IF, where: 1 = (R)-2-
DCl-IF, 2 = (S)-3-DCl-IF and B. (S)-IF where: 3 = (S)-2-DClIF, 4 = (R)-3-DCl-IF. The reaction
mixtures were analyzed using the Chirabiotic T CSP using mobile phases 2-propanol:methanol
(60:40 v/v) at a flow rate of 0.5 ml/min and mass spectrometric detection at m/z 283.0 (IF) and
m/z 199.1 (2-DCl-IF, 3-DCl-IF).
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Chromatograms of plasma samples obtained from a patient where: A. pre-dose; B. 6 h after
the end of a 96-h infusion of 3.75g/m2/d (R,S)-IF. The observed peaks correspond to
concentrations of: (S)-IF = 3.66 μg/ml; (R)-IF = 6.29 μg/ml; (S)-2-DCl-IF = 3.64 μg/ml; (R)-2-
DCl-IF = 0.887 μg/ml; (S)-3-DCl-IF = 3.70 μg/ml and (R)-3-DCl-IF = 2.27 μg/ml. where: (1)
= (S)-2-DCl-IF; (2) = (R)-2-DCL-IF; (3) = (S)-3-DClIF; (4) = (R)-3-DCl-IF.
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Plasma concentration-time curve of IF, 2-DCl-IF and 3-DCl-IF determined in a patient who
had received a 96-h infusion of 3.75g/m2/d (R,S)-IF and who was sampled for an additional
24-h post-infusion period.
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